心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

2021 加拿大专家共识：癌症相关血栓形成的治疗流程

2021-12-18 国外肿瘤科相关专家小组（统称） Curr Oncol

癌症相关血栓形成

癌症相关血栓形成（CAT）患者复发性静脉血栓栓塞（VTE）和严重出血并发症风险高，本文主要针对CAT的治疗提供共识指导。

中文标题：

2021 加拿大专家共识：癌症相关血栓形成的治疗流程

英文标题：

Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus

发布机构：

国外肿瘤科相关专家小组（统称）

发布日期：

2021-12-18

简要介绍：

癌症相关血栓形成（CAT）患者复发性静脉血栓栓塞（VTE）和严重出血并发症风险高，本文主要针对CAT的治疗提供共识指导。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 加拿大专家共识：癌症相关血栓形成的治疗流程.pdf)] GetToolGuiderByIdResponse(projectId=1, id=38b521c002301267, title=2021 加拿大专家共识：癌症相关血栓形成的治疗流程, enTitle=Treatment Algorithm in Cancer-Associated Thrombosis: Updated Canadian Expert Consensus, guiderFrom=Curr Oncol, authorId=0, author=, summary=癌症相关血栓形成（CAT）患者复发性静脉血栓栓塞（VTE）和严重出血并发症风险高，本文主要针对CAT的治疗提供共识指导。, cover=https://img.medsci.cn/20211224/1640353760994_1608702.jpg, journalId=0, articlesId=null, associationId=887, associationName=国外肿瘤科相关专家小组（统称）, associationIntro=null, copyright=0, guiderPublishedTime=Sat Dec 18 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">癌症相关血栓形成（CAT）患者复发性静脉血栓栓塞（VTE）和严重出血并发症风险高，本文主要针对CAT的治疗提供共识指导。</span></p>, tagList=[TagDto(tagId=83531, tagName=癌症相关血栓形成)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=83531, guiderKeyword=癌症相关血栓形成, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=6, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=1634, appHits=88, showAppHits=0, pcHits=335, showPcHits=1546, likes=0, shares=19, comments=5, approvalStatus=1, publishedTime=Fri Dec 24 21:44:54 CST 2021, publishedTimeString=2021-12-18, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Fri Dec 24 21:55:04 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 14:51:30 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 加拿大专家共识：癌症相关血栓形成的治疗流程.pdf)])
2021 加拿大专家共识：癌症相关血栓形成的治疗流程.pdf
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1085802, encodeId=46fd10858022f, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98ad6192838, createdName=66304_9712, createdTime=Thu Dec 30 12:58:01 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085034, encodeId=32e0108503463, content=学习学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=210b4868969, createdName=278103059, createdTime=Tue Dec 28 10:00:38 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084852, encodeId=b2f0108485295, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe925425978, createdName=ms8000000973640961, createdTime=Mon Dec 27 20:39:18 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084549, encodeId=b2941084549ac, content=嘻嘻嘻, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211225/717112a900ad4bfcba1d6a36b3a61357/251acdeb515d4c43a7061d446138851e.jpg, createdBy=dbdc6411707, createdName=虢, createdTime=Mon Dec 27 01:26:38 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084312, encodeId=3e01108431255, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Dec 26 07:32:44 CST 2021, time=2021-12-26, status=1, ipAttribution=)]
    2021-12-30 66304_9712

    学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1085802, encodeId=46fd10858022f, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98ad6192838, createdName=66304_9712, createdTime=Thu Dec 30 12:58:01 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085034, encodeId=32e0108503463, content=学习学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=210b4868969, createdName=278103059, createdTime=Tue Dec 28 10:00:38 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084852, encodeId=b2f0108485295, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe925425978, createdName=ms8000000973640961, createdTime=Mon Dec 27 20:39:18 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084549, encodeId=b2941084549ac, content=嘻嘻嘻, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211225/717112a900ad4bfcba1d6a36b3a61357/251acdeb515d4c43a7061d446138851e.jpg, createdBy=dbdc6411707, createdName=虢, createdTime=Mon Dec 27 01:26:38 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084312, encodeId=3e01108431255, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Dec 26 07:32:44 CST 2021, time=2021-12-26, status=1, ipAttribution=)]
    2021-12-28 278103059

    学习学习啦

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1085802, encodeId=46fd10858022f, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98ad6192838, createdName=66304_9712, createdTime=Thu Dec 30 12:58:01 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085034, encodeId=32e0108503463, content=学习学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=210b4868969, createdName=278103059, createdTime=Tue Dec 28 10:00:38 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084852, encodeId=b2f0108485295, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe925425978, createdName=ms8000000973640961, createdTime=Mon Dec 27 20:39:18 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084549, encodeId=b2941084549ac, content=嘻嘻嘻, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211225/717112a900ad4bfcba1d6a36b3a61357/251acdeb515d4c43a7061d446138851e.jpg, createdBy=dbdc6411707, createdName=虢, createdTime=Mon Dec 27 01:26:38 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084312, encodeId=3e01108431255, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Dec 26 07:32:44 CST 2021, time=2021-12-26, status=1, ipAttribution=)]
    2021-12-27 ms8000000973640961

    1

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1085802, encodeId=46fd10858022f, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98ad6192838, createdName=66304_9712, createdTime=Thu Dec 30 12:58:01 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085034, encodeId=32e0108503463, content=学习学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=210b4868969, createdName=278103059, createdTime=Tue Dec 28 10:00:38 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084852, encodeId=b2f0108485295, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe925425978, createdName=ms8000000973640961, createdTime=Mon Dec 27 20:39:18 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084549, encodeId=b2941084549ac, content=嘻嘻嘻, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211225/717112a900ad4bfcba1d6a36b3a61357/251acdeb515d4c43a7061d446138851e.jpg, createdBy=dbdc6411707, createdName=虢, createdTime=Mon Dec 27 01:26:38 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084312, encodeId=3e01108431255, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Dec 26 07:32:44 CST 2021, time=2021-12-26, status=1, ipAttribution=)]
    2021-12-27 虢

    嘻嘻嘻

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1085802, encodeId=46fd10858022f, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=98ad6192838, createdName=66304_9712, createdTime=Thu Dec 30 12:58:01 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085034, encodeId=32e0108503463, content=学习学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=210b4868969, createdName=278103059, createdTime=Tue Dec 28 10:00:38 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084852, encodeId=b2f0108485295, content=1, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe925425978, createdName=ms8000000973640961, createdTime=Mon Dec 27 20:39:18 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084549, encodeId=b2941084549ac, content=嘻嘻嘻, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211225/717112a900ad4bfcba1d6a36b3a61357/251acdeb515d4c43a7061d446138851e.jpg, createdBy=dbdc6411707, createdName=虢, createdTime=Mon Dec 27 01:26:38 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084312, encodeId=3e01108431255, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Sun Dec 26 07:32:44 CST 2021, time=2021-12-26, status=1, ipAttribution=)]
    2021-12-26 微探

    学习学习

    0

相关指南

2020 ITAC-CME临床实践指南：直接口服抗凝剂时期癌症相关血栓形成的管理

国际血栓形成和癌症创议(ITAC-CME,International Initiative on Thrombosis and Cancer) · 2020-02-01

2018 加拿大专家共识：癌症相关血栓形成的治疗策略

国外肿瘤科相关专家小组（统称） · 2018-10-31

拓展阅读

2018 加拿大专家共识：癌症相关血栓形成的治疗策略

国外肿瘤科相关专家小组（统称） · 2018-10-31

2020 ITAC-CME临床实践指南：直接口服抗凝剂时期癌症相关血栓形成的管理

国际血栓形成和癌症创议(ITAC-CME,International Initiative on Thrombosis and Cancer) · 2020-02-01